(12) Patent Application Publication (10) Pub. No.: US 2005/0181077 A1 Asiedu Et Al
Total Page:16
File Type:pdf, Size:1020Kb
US 2005O181077A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0181077 A1 Asiedu et al. (43) Pub. Date: Aug. 18, 2005 (54) COMPOSITION TREATING FOR AIDS AND Publication Classification ASSOCATED CONDITIONS (51) Int. Cl." ..................................................... A61K 35/78 (76) Inventors: William Asiedu, Accra (GH); (52) U.S. Cl. ............................................ 424/725; 424/769 Frederick Asiedu, Accra (GH); Manny Ennin, Accra (GH); Michael Nsiah (57) ABSTRACT Doudu, Accra (GH); Charles Antwi An Aids and associated conditions related to Aids treating Boateng. Accra (GH); Kwasi compositions is disclosed. The compositions comprise: a Appiah-Kubi, Accra (GH); Seth medicament Selected from an extract of at least one of the Opoku Ware, Accra (GH); Debrah following plant families: Apocynaceae (PleioScarpa Bicar Boateng. Accra (GH); Kofi Ampim, pellata); Annonaceae (Cleistopholis Patens); Dichapetal Accra (GH); William Owusu, Accra aceae (Dichapetehan Madagasca Riense); Annoceae (GH); Akwete Lex Adjei, Bridgewater, (Uvaristrum Pierreanum); Cynocynaceae (Strophantus Gra NJ (US) tus); Asclepiadaceae (GongrOnema Latifolium); Combreta Correspondence Address: ceae (Combretum Racemosum), Apocynaceae (AloStonia BOOnei); Amaranthaceae (Altemanthera Pungens); Aroceae FROMMER LAWRENCE & HAUG (Anchomanes Differmis); Cyperaceae (Seleria Voivinil); 745 FIFTHAVENUE- 10TH FL. Anacardiaceae (Lannea Acida); Bignoniaceae (Kigelia Afri NEW YORK, NY 10151 (US) cana); Bombacaceae (Ceiba Pentanoia); Anarcardiaceae (21) Appl. No.: 10/902,993 (Antrocaryon Micraster); Bombacaceae (Bombax Bounopo zense): Anarcardiaceae (Spondias Mombin); Caricaceae (22) Filed: Jul. 30, 2004 (Carica Papaya); a glyceryl ester of any of the foregoing extracts, a Saponin of any of the foregoing extracts, an Related U.S. Application Data alkaloid of any of the foregoing extracts, a protein of any of the foregoing extracts, a fat of any of the foregoing extracts, (63) Continuation of application No. 10/241,973, filed on a Sugar of any of the foregoing extracts, and any mixture of Sep. 12, 2002, now abandoned. any of the foregoing. US 2005/0181.077 A1 Aug. 18, 2005 COMPOSITION TREATING FOR AIDS AND be reportable in some states and cities but will not be ASSOCATED CONDITIONS nationally reportable. Because perSons with less Specific or milder manifestations of HTLV-III(LAV infection may be BACKGROUND OF THE INVENTION important in transmitting the virus, estimates of the number of Such perSons are of value. These estimates can be 0001) 1. Field of the Invention obtained through epidemiologic Studies or special Surveys in 0002 This invention relates to a composition for treating Specific populations. AIDS and related conditions, and more particular, to a 0007 Issues related to the case definition of AIDS were composition comprising at least one extract of a Selected discussed by the Conference of State and Territorial Epide plant. miologists (CSTE) at its annual meeting in Madison, Wis., Jun. 2-5, 1985. The CSTE approved the following resolu 0003 2. Description of the Prior Art tions: 0004 Patients with illnesses that, in retrospect, were manifestations of acquired immunodeficiency Syndrome 0008 1. that the case definition of AIDS used for (AIDS) were first described in the summer of 1981 CDC national reporting continue to include only the more Pneumocystis pneumonia-Los Angeles. MMWR 1981, severe manifestations of HTLV-III/LAV infection; 30:250-2; CDC-Kaposi's Sarcoma and Pneumocystis and pneumonia among homosexual men-New York City and 0009 2. that the Center For Disease Control (CDC) California. MMWR 1981, 30:305-8). A case definition of develop more inclusive definitions and classifica AIDS for national reporting was first published in the tions of HTLV-III/LAV infection for diagnosis, treat MMWR in September 1982 CDC-Hepatitis B virus vac ment, and prevention, as well as for epidemiologic cine Safety. report of an inter-agency group MMWR 1982, Studies and Special Surveys, and 31:465-67; CDC-Update On acquired immune deficiency syndrome (AIDS)-United States. MMWR 1982, 31:507 0010) 3. that the following refinements be adopted in 14. Since then the definition has undergone minor revisions the case definition of AIDS used for national report in the list of diseases used as indicators of underlying ing: cellular immunodeficiency Jaffe HW, Bregman DJ, Selik 0.011 a. In the absence of the opportunistic dis R M. Acquired immune deficiency Syndrome in the United easeS required by the current case definition, any States: the first 1,000 cases. J Infect Dis 1983, 148:339-45; of the following diseases will be considered Jaffe H W, Selik R. M. Acquired immune deficiency Syn indicative of AIDS if the patient has a positive drome: is disseminated aspergillosis predictive of underly serologic or virologic test for HTLV-III/LAV: ing cellular immune deficiency?, (Reply to letter), J Infect Dis 1984, 149:829; Selik RM, Haverkos H W. Curran J W. 0012 1. disseminated histoplasmosis (not confined Acquired immune deficiency Syndrome (AIDS) trends in the to lungs or lymph nodes), diagnosed by culture, United States, 1978-1982. Am J Med 1984, 76:493-500; histology, or antigen detection; CDC, Update: acquired immunodeficiency Syndrome 0013 2. isosporiasis, causing chronic diarrhea (over (AIDS)–United States. MMWR 1984, 32:688-91) 1 month), diagnosed by histology or stool micros 0005 Since the 1982 definition was published, human copy; T-cell lymphotropic virus type III/lymphadenopathy-associ 0014) 3. bronchial or pulmonary candidiasis, diag ated virus (HTLV-III/LAV) has been recognized as the cause nosed by microScopy or by presence of characteristic of AIDS. The clinical manifestations of (HTLV-III/LAV) white plaques grossly on the bronchial mucosa (not infection may be directly attributable to infection with this Virus or the result of Secondary conditions occurring as a by culture alone); consequence of immune dysfunction caused by the under 0015 4. non-Hodgkins' lymphoma of high-grade lying infection with (HTLV-III/LAV). The range of mani pathologic type (diffuse, undifferentiated) and of festations may include none, nonspecific signs and Symp B-cell unknown immunologic phenotype, diagnosed toms of illness, autoimmune and neurologic disorders, a by biopsy; variety of opportunistic infections, and Several types of 0016 5. histologically confirmed Kaposi's sarcoma malignacy. AIDS was defined for national reporting before in patients who are 60 years old or older when its etiology was known and has encompassed only certain diagnosed. Secondary conditions that reliably reflected the presence of a Sever immune dysfunction. Current laboratory tests to 0017 b. In the absence of the opportunistic dis detect (HTLV-III/LAV) antibody make it possible to include easeS required by the current case definition, a additional Serious conditions in the Syndrome, as well as to histologically confirmed diagnosis of chronic lym further improve the specificity of the definition used for phoidinterstitial pneumonitis in a child (under 13 reporting cases. years of age) will be considered indicative of AIDS unless test(s) for HTLV-III/LAV are nega 0006. The current case definition of AIDS has provided tive. useful data on disease trends, because it is precise, consis tently interpreted, and highly specific. Other manifestations 0.018 c. Patients who have a lymphoreticular of HTLV-III/LAV infections than those currently proposed malignancy diagnosed more than 3 months after to be reported are leSS Specific and less likely to be consis the diagnosis of an opportunistic disease used as a tently reported nationally. Milder disease associated with marker for AIDS will no longer be excluded as HTLV-III/LAV infections and asymptomatic infections may AIDS cases. US 2005/0181.077 A1 Aug. 18, 2005 0019 d. To increase the specificity of the case phellodendron amureause, and Sepia aculeata. The medicine definition, patients will be excluded as AIDS cases is used in Such a manner that the powdered basis part is if they have a negative result on testing for Serum mixed and Stirred with tea water until it becomes plaster antibody to HTLV-III/LAV, have no other type of like, and the adjuvant part is Scattered in dry form onto the HTLV-III/LAV test with a positive result, and do wound or Swollen area caused by the black foot disease not have a low number of T-helper lymphocytes or before the plaster-like basis part is applied to the wound or a low ratio of T-helper to T-SuppreSSor lympho Swollen area about 0.5 cm in thickness. The wound is then cytes. In the absence of test results, patients Sat bandaged and the medicine is renewed once or twice a day isfying all other criteria in the definition will until fresh flesh appears in the wound. Thereafter, the continue to be included. CDC will immediately medicine is continuously applied but in a dry form until the adopt the above amendments to the case definition wound is completely healed. The extract medicament com of AIDS for national reporting. position taught by Chen et al., does not have any impact on AIDS itself as a systemic disease. 0020. This revision, in the case definition will result in the reclassification of less than 1% of cases previously SUMMARY OF THE INVENTION reported to CDC. The number of additional new cases reportable as a result of the revision is expected to be Small. 0023 The present invention is related to a composition Cases included under the revised definition will be distin for treating AIDS and associated